We examined the recovery of circulating monocytoid (Lin
cytoid DC; stem cell transplantation; acute GVHD Dendritic cells (DC) are a heterogeneous group of rare bone marrow-derived leukocytes that are uniquely well equipped for antigen capture, processing and presentation. 1 They are critically important in the initiation and regulation of allogeneic immune responses, 2, 3 and play significant roles in GVH reactivity and in the recovery of immunity. [4] [5] [6] [7] DC precursors (preDC) reach peripheral tissues through the blood stream. In humans, at least three subtypes of circulating HLA-DR þ preDC have been described. [8] [9] [10] [11] Blood monocytes (CD14 þ ) can differentiate either into DC or macrophages, depending on the cytokine environment. Two other subsets of blood-borne preDC do not display lineage markers (eg CD3, CD14, CD19, CD20 or CD56) but express HLA-DR and either CD11c or CD123 (IL-3 receptor a-chain). PreDC expressing CD11c (designated herein as monocytoid DC) belong to the same lineage as monocyte-derived DC, and promote differentiation of T helper (Th)1 cells. 4, 12 PreDC expressing CD123 (designated herein as plasmacytoid DC) are dependent on IL-3 but not granulocyte colony-stimulating factor (GM-CSF) for growth and survival, and produce interferon a/b upon activation with microbial products or CD40L (that mimics contact with activated T cells). 13, 14 Early work suggested that plasmacytoid DC mature into DC that drive Th2-cell differentiation, 12 but more recent evidence indicates that both DC subsets can promote the differentiation of Th1 or Th2 cells depending on antigen dose and quality, and the cytokine milieu in which the DC subsets mature. [15] [16] [17] There is also evidence that DC can induce T regulatory cells. [18] [19] [20] In this study, we have examined the recovery of circulating monocytoid and plasmacytoid DC subsets after allogeneic stem cell transplantation (SCT) in children, using age-matched healthy children as controls. 21 Recovery of DC was related to general myeloid recovery monitored by WBC and absolute granulocyte levels in blood.
Patients and methods

Study population
The study included 39 SCT patients who were transplanted and studied at the Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, University of Helsinki, Finland (Table 1) . Informed consent was obtained from age-appropriate patients and their parents. Diagnosis and grading of acute and chronic graft-versus-host disease (aGVHD and cGVHD) were made according to generally accepted criteria. [22] [23] [24] The study was approved by the Institutional Review Board.
Early post transplant group
Nine patients were transplanted during the study, and were assessed prospectively in the early post transplant period (o100 days from SCT). Samples for analysis of the rapidity of DC recovery after SCT were collected from patients whose absolute granulocytes in peripheral blood exceeded 0.5 Â 10 9 /l, indicating successful engraftment and either no or mild aGVHD (grades 0-II). Eight out of nine patients were eligible and were sampled 17-33 days (median 26.5 days) post SCT. One patient was excluded because of grade III aGVHD.
To study the influence of aGVHD on the peripheral blood DC count, samples (n ¼ 28) were drawn from all nine patients in the early post transplant group at various time points post SCT. Samples were divided into two groups depending on the patients' aGVHD grade at the time of sampling. Mild aGVHD group (grades 0-II) was represented by 14 samples from eight patients, and severe aGVHD (grades III-IV) by 14 samples from four patients.
Within each group each patient was represented by only one DC count. Thus, if a patient was assessed more than once, a mean DC count was calculated for that patient.
Late post transplant group
In all, 33 patients attending the outpatient clinic in the course of their regular follow-up were assessed 4100 days from SCT. Three of these patients were also included in the early post transplant group. Patients were considered eligible if no signs or symptoms of acute infections were evident. Each patient was assessed once at each time point.
Age-matched control patients
We have shown recently that peripheral blood DC counts in children are age dependent. 21 For the present study, agematched controls were 39 children whose demographics and DC counts have been described in detail. 21 These children were otherwise healthy, but had been admitted with orthopedic indications including scoliosis or other skeletal abnormalities. The children's medical charts and health status were examined by one investigator (JV), and only patients free of infections, with no systemic diseases and not on any drugs affecting the immune system or hematopoiesis were accepted. Samples were drawn at presentation and before any surgical procedures were performed. Since we are not aware of any hematologic abnormalities associated with isolated skeletal abnormalities, the children were considered appropriate as controls.
Use of G-CSF and immunosuppressive treatment after SCT
Seven of nine patients in the early post transplant group received G-CSF after transplantation starting from day 1 until recovery of absolute neutrophil count higher than 1 Â 10 9 /l. Patients with myeloid or mixed lineage malignancies did not receive G-CSF (n ¼ 2).
aGVHD prophylaxis for patients receiving allogeneic stem cells from a sibling donor included cyclosporin A (CyA) (initial blood concentration 100 mg/ml) for a period of 6 months and 10 mg/m 2 of intravenous methotrexate (days þ 1, þ 3, þ 6 post transplantation). Patients who received stem cells from an unrelated register donor were treated with higher doses of CyA (initial blood concentration 200 mg/ml) lasting for 18 months and 10 mg/m 2 of intravenous methotrexate (days þ 1, þ 3, þ 6, þ 11). Corticosteroids (CS) were not included in the prophylaxis.
Grade I-II aGVHD on skin was treated with extra doses of intravenous methotrexate 10 mg/m 2 . More severe aGVHD or liver or gut aGVHD was treated by intravenous methylprednisolone 2 mg/kg/day unless contraindications existed. These included very aggressive malignant disease, or severe life-threatening viral or fungal infections. In these patients (n ¼ 3), treatment with CS was delayed as far as possible or alternative immunosuppressive drugs including azathioprine, or mycophenolate mofetil were used. 
Blood sampling and staining for determination of DC counts
Peripheral venous blood samples for DC enumeration were drawn into heparinized tubes and cells stained within 2 h of collection. DC were enumerated using FITC-conjugated monoclonal antibodies (mAbs) directed against leukocyte lineage markers (Lin; anti-CD3, -CD14, -CD16, -CD19, -CD20, -CD56), PE-conjugated anti-CD11c, PE-conjugated anti-CD123 and PerCP-conjugated anti-HLA-DR. Appropriate isotype control mouse immunoglobulin (Ig)G1 and mouse IgG2a were also used. All mAbs and control Igs were purchased from BD PharMingen (San Diego, CA, USA). mAb staining was performed according to the manufacturer's instructions: two whole-blood samples (100 ml) drawn from each patient were incubated with 20 ml of the lineage cocktail FITC, 10 ml anti-HLA-DR PerCP and either 5 ml anti-CD11c PE, 5 ml anti-CD123 PE or the appropriate isotype controls. The samples were incubated for 15 min at room temperature in the dark. Red cells were lysed with lysing solution (BD PharMingen), and incubation continued for an additional 10 min. The cells were then washed twice in phosphate-buffered saline.
Identification and enumeration of DC subsets in whole-blood samples by flow cytometric analysis
Events were acquired on a FACScan flow cytometer (BD PharMingen) equipped with filter settings for FITC (530 nm), PE (585 nm) and PerCP fluorochromes (4650 nm). Data analysis was performed using 'Cell Quest' software (BD PharMingen). Dead cells and platelets were gated out before the final analysis using side-scatter/ forward-scatter dot-plots. A minimum of 7 Â 10 4 WBC were acquired per analysis. The procedure for identification and enumeration of DC subsets has been described; 21, [25] [26] [27] [28] cells expressing lineage markers were excluded (a threshold for Lin þ and Lin À cells was determined using isotype control Igs) and the proportions of strongly HLA-DR
þ (plasmacytoid DC) cells determined. Absolute DC values were calculated for each child using the percentage of DC and total WBC. The WBC count was determined by Advia 120 Hematology System (Bayer Corporation, Tarrytown, NY, USA).
Statistical analysis
Statistical analyses were performed with SPSS for Windows 11.01 version (SPSS Inc., Chicago, Il, USA). A nonparametric Mann-Whitney U-test was used for all data, except time-related changes in DC counts, which were analyzed by linear and logarithmic regression analysis.
Results
Recovery of DC production during the early post transplant period (days 17-121)
Eight patients, whose myeloid engraftment had been confirmed by blood granulocyte counts and without severe aGVHD, were analyzed to assess the initial recovery of circulating DC. No significant differences in the absolute
were observed between these SCT patients and the age-matched controls (Figure 1 ), suggesting that both DC subsets recover simultaneously with other myeloid cells.
Time-related changes during the early post transplant period were analyzed irrespective of the aGVHD status of the patients (33 samples from 13 patients). Linear regression analysis revealed a significant negative correlation between DC subsets and time after SCT (monocytoid DC, r ¼ À0.586, Po0.001; plasmacytoid DC, r ¼ À0.389, P ¼ 0.025). Thus, both DC subsets in blood declined with time during the first 100 days post SCT (Figure 2b and c) . The decreased DC values did not reflect general dysfunction of bone marrow, since patients' WBC did not decrease concurrently with the DC counts (Figure 2a) .
By definition, aGVHD develops during the first 100 days post SCT. Out of nine tested patients, eight were assessed while having no or mild aGVHD (14 samples) and four while suffering from severe aGVHD (14 samples). Absolute monocytoid DC counts were significantly lower in patients with severe aGVHD compared with mild aGVHD (P ¼ 0.042) (Figure 3a) . The medians were 4.9 and 17.9 monocytoid DC/ml, respectively. Plasmacytoid DC counts during severe aGVHD were almost undetectable, being 0.9 cells/ml (median). This was significantly less than 6.3 plasmacytoid DC/ml in patients with mild aGVHD (Po0.017) (Figure 3b) . Importantly, WBC counts were not lower in the severe aGVHD group but higher being 7.2 Â 10 9 /l and 3.0 Â 10 9 /l (P ¼ 0.027). As aGVHD progresses with time, median follow-up time after SCT was significantly longer in the severe aGVHD group than in the mild aGVHD group; 56.5 vs 30 days, respectively (P ¼ 0.001). CS are commonly used to treat aGVHD, making it difficult to distinguish their influence on DC frequencies in blood. As shown in Figure 2 , patients on steroids had relatively low DC counts (open diamonds), but similarly low counts were also observed in patients not receiving steroids (black diamonds). Three patients developing severe aGVHD were followed longitudinally with repeated sampling, and one of those did not receive CS due to complicating human herpesvirus-6 encephalitis (Figure 4c ). Her immunosuppression consisted of CyA and azathioprine. Despite this difference, DC counts behaved remarkably similarly in all three patients, decreasing concurrently with the worsening symptoms of aGVHD and after 40 days from SCT (Figure 4) . The patient receiving azathioprine ( Figure 4c ) had a parallel decrease in WBC but not those on CS (Figure 4a and b) .
URD recipients (two patients) received a higher dose of CyA than MSD recipients as prophylaxis for GVHD, and six out of eight patients received G-CSF to facilitate engraftment. Variations in the use of CyA or G-CSF had no apparent influence on the recovery of DC (data not shown).
Circulating DC numbers in the late post transplant period (4100 days)
Peripheral blood DC numbers were studied in 33 SCT patients who had passed the acute period (4100 days), and were in continuous remission. The median follow-up time from SCT was 315 days (range: 102-2569 days). Absolute DC counts in SCT patients were analyzed by logarithmic regression analysis ( Figure 5 ). Both monocytoid and plasmacytoid DC counts were dependent on the followup time (P ¼ 0.012 and 0.023, respectively) being higher longer after transplant. Whereas monocytoid DC values approached normal levels at around 300-400 days from SCT ( Figure 5b ; the dashed line represents the median for age-matched control children), plasmacytoid DC counts recovered much more slowly ( Figure 5c ) and remained below the reference line for the entire follow-up period.
The ratio of plasmacytoid to monocytoid DC (0.29) was also significantly lower than that in the controls (0.45; P ¼ 0.005). WBC in these patients did not differ from control patients, and were not related with time ( Figure 5a ). Patients were subdivided into three groups: no cGVHD (n ¼ 17), limited cGVHD (n ¼ 9) and extensive cGVHD (n ¼ 7). No significant differences were observed in monocytoid or plasmacytoid DC numbers in relation to severity of cGVHD (Table 2) . Nine patients received an MSD graft and their median monocytoid and plasmacytoid DC counts were 17.3 and 4.5 cells/ml, respectively. These values were not significantly different from those of the URD-graft recipients (n ¼ 23) (12.7 and 4.1 cells/ml). A striking positive correlation, however, was found between URD transplantation and development of cGVHD (Pearson's correlation coefficient, 0.416, P ¼ 0.016). Seven patients were on CS at the time of sampling (marked as open circles, Figure 5 ). DC counts in these patients were compared with those of 13 other patients, who were sampled within the same time range post SCT (102-473 vs 103-459 days, P ¼ NS) and not on CS. CS treatment was associated with significantly lower monocytoid DC counts (medians 8.9 vs 17.1 DC/ml, P ¼ 0.039) but unaffected plasmacytoid DC levels (3.6 vs 4.2 DC/ml, P ¼ NS). 
Discussion
A recent study by Fagnoni et al 29 in which 43 children were followed immediately after SCT showed that initially DC counts were somewhat higher in those children who later on developed aGVHD than in uncomplicated cases. Progression of aGVHD or use of CS in their study was associated especially with decreasing plasmacytoid DC values. Furthermore, in G-CSF-treated children, immediate recovery of both myeloid and plasmacytoid DC counts were rapid and prominent, but thereafter the blood levels decreased being at the lowest level 40-60 days post SCT. Our results are remarkably similar with those of Fagnoni et al. We show here that the initial recovery of DC production in children occurred concurrently with myeloid engraftment. However, with time, DC subset values declined, being very low 40-50 days from SCT. Lower values also associated significantly with the development of severe aGVHD. Since we had patients who did not receive CS immediately after the beginning of aGVHD, we were able to see the decline in DC counts even without the use of CS.
Earlier studies of adults have shown a positive correlation between decreased DC counts and severity of aGVHD. 30, 31 The association of low plasmacytoid DC counts with aGVHD is of considerable interest since it has been suggested that plasmacytoid DC originating either from the graft 32 or host hematopoietic stem cells 33, 34 can suppress the development of aGVHD. Also, relative dominance of the CD123 þ DC subset over the CD11c þ DC subset is associated with successful weaning of immunosuppression in liver transplant patients 27 and with poor prognosis in children with cancer. 21 There are reports that use of CS leads to decreased blood DC in various human disorders, including GVHD. 29, 30, 35, 36 Since CS are usually the first choice treatment for aGVHD, it is very difficult to distinguish their influence on blood DC numbers from that of the disease. One patient in our study group, however, did not receive CS treatment despite progression of her aGVHD, and her plasmacytoid DC counts did decrease similarly to those of other patients. Thus, low DC counts seem to occur in the context of aGVHD even in the absence of CS treatment. Yet, the influence of other immunosuppressive drugs including azathioprine cannot be excluded.
It is possible that lower DC counts in our study population were merely associated with longer follow-up time rather than severity of aGVHD, since the median sampling time was higher in the severe GVHD group than in the mild GVHD group (56.5 and 28 days, respectively; Po0.001). If this were the case, DC values would decrease after initial engraftment also in patients who do not develop aGVHD. In fact, Arpinati et al 30 reported that in adult patients without aGVHD, plasmacytoid DC values were lower at 3 months than at 1 month post SCT (3.1 vs 4.9 DC/ml, respectively). It could be that DC values are at the lowest level in all SCT patients 2-3 months post transplant and this decrease is not necessarily dependent on the presence of complicating GVHD.
The other study population consisted of children who were transplanted 4100 days previously. In accordance with the early post transplant group, absolute DC counts were at their lowest level in the beginning of the follow-up period (100 days post SCT) and thereafter recovered slowly. Normal monocytoid DC counts appeared in blood approximately 10-13 months post allogeneic SCT, but plasmacytoid DC remained low for the entire follow-up period (up to 3-6 years post SCT). Nevertheless, a steady, time-dependent increase in plasmacytoid DC counts was observed, indicating that, with time, normal plasmacytoid DC counts are also achieved in SCT patients. The slow recovery rate of plasmacytoid DC has also been observed in adult SCT patients. 37 Studies in adult SCT patients have indicated that cGVHD is associated with high plasmacytoid DC numbers. 32, 38 We were not able to find any relationship between DC counts and cGVHD in our pediatric SCT population. Since both plasmacytoid DC counts 21, 25 and the incidence of cGVHD after SCT 39 are age dependent, being lower and more frequent in adults than children, the lack of correlation between cGVHD and DC counts in our study may be related to the age of the patients.
In conclusion, our study of children after SCT has revealed low DC counts, especially those of plasmacytoid DC in the context of aGVHD. Normal levels of monocytoid DC are observed in the blood approximately 1 year after SCT, but plasmacytoid DC recover more slowly, and are below normal up to several years post SCT. No correlation between DC counts and cGVHD during the chronic phase was observed.
